Technical Analysis for ADRO - Aduro Biotech, Inc.

Grade Last Price % Change Price Change
grade F 1.25 -3.10% -0.04
ADRO closed down 3.1 percent on Wednesday, September 18, 2019, on 66 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ADRO trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish -3.10%
20 DMA Support Bullish -3.10%
20 DMA Support Bullish -7.41%
Crossed Above 50 DMA Bullish -7.41%
180 Bullish Setup Bullish Swing Setup -7.41%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -7.41%
50 DMA Resistance Bearish -3.10%
20 DMA Support Bullish -3.10%
50 DMA Resistance Bearish -6.72%

Older signals for ADRO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Aduro BioTech, Inc., a clinical-stage immuno-oncology company, focuses on the development of technology platforms designed to stimulate robust and durable immune responses against cancer. Its lead product candidate is CRS-207, which is in a Phase IIb clinical trial for the treatment of metastatic pancreatic cancer and unresectable malignant pleural mesothelioma. The company's cyclic dinucleotides product candidates are synthetic small molecule immune modulators that target and activate Stimulator of Interferon Genes receptor. Aduro BioTech, Inc. has collaboration agreement with Janssen Biotech, Inc. to develop drugs for the treatment of prostate and lung cancers. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.
Medicine Cancer Cancer Immunotherapy Technology Platforms Metastatic Pancreatic Cancer Johnson & Johnson Lung Cancers
Is ADRO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.64
52 Week Low 1.15
Average Volume 359,805
200-Day Moving Average 2.6703
50-Day Moving Average 1.3365
20-Day Moving Average 1.2768
10-Day Moving Average 1.293
Average True Range 0.0866
ADX 25.28
+DI 13.7425
-DI 20.5807
Chandelier Exit (Long, 3 ATRs ) 1.1602
Chandelier Exit (Short, 3 ATRs ) 1.4098
Upper Bollinger Band 1.3847
Lower Bollinger Band 1.1689
Percent B (%b) 0.38
BandWidth 16.901629
MACD Line -0.0194
MACD Signal Line -0.0307
MACD Histogram 0.0113
Fundamentals Value
Market Cap 93.27 Million
Num Shares 74.6 Million
EPS -1.56
Price-to-Earnings (P/E) Ratio -0.80
Price-to-Sales 35.46
Price-to-Book 2.36
PEG Ratio 0.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.40
Resistance 3 (R3) 1.41 1.37 1.38
Resistance 2 (R2) 1.37 1.33 1.37 1.37
Resistance 1 (R1) 1.31 1.31 1.29 1.30 1.36
Pivot Point 1.27 1.27 1.26 1.27 1.27
Support 1 (S1) 1.21 1.23 1.19 1.20 1.14
Support 2 (S2) 1.17 1.21 1.17 1.13
Support 3 (S3) 1.11 1.17 1.13
Support 4 (S4) 1.10